Bioxyne Ltd

Bioxyne Limited’s latest filings show a dual strategy to raise cash and boost market visibility amid low share prices, offering investors a detailed look at the company’s capital‑raising tactics and regulatory transparency.

Bioxyne Ltd, a biotechnology company focused on chronic obstructive pulmonary disease (COPD) treatments, is navigating a challenging path to commercial success, with its share price and financial metrics raising concerns about its financial stabilit…

Bioxyne Ltd, a biotechnology company specializing in COPD products, has set ambitious revenue and EBITDA targets for FY2026, driven by expansion in Australia and entry into new international markets.

Bioxyne Ltd is a pioneering Australian company that is making a significant impact in the biotechnology and personal care industries through its innovative products and commitment to addressing chronic obstructive pulmonary disease (COPD).